Authors

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology

Latest:

The Future of Endometrial Cancer Treatment

Experts give insight on what they are looking forward to in the endometrial cancer space.

Bradley J. Monk, MD, University of Arizona

Bradley J. Monk, MD, University of Arizona Cancer Center

Bradley McGregor, MD

Latest:

Dr McGregor on Future Biomarker Analyses With Nivolumab Plus Ipilimumab in Bladder Cancer

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Bradley McGregor, MD, Dana-Farber Cancer Institute

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

Bradley Monk, MD, FACOG, FACS, St. Joseph's Hospital

Brady L. Stein, MD

Latest:

Dr. Stein Discusses Changes to the NCCN Guidelines in MPNs

Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

Brandon G. Smaglo, MD, FACP

Latest:

Dr Smaglo on the Evolution of RAS-Targeted Therapies for Pancreatic Cancer

Brandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer.

Brandon Huffman, MD

Latest:

Dr Huffman on the Investigation of Azenosertib Plus Gemcitabine in Advanced Pancreatic Cancer

Brandon Huffman, MD, discusses an ongoing phase 2 trial evaluating azenosertib plus gemcitabine in advanced pancreatic cancer.

Brandon May

Latest:

Cota-Watson Effort Aims at Optimal Cost Margins as Well as Improved Care

Investigators at Cota, a New York medical data analytics company, are taking further strides toward putting their growing knowledge of variance in care to work in the clinical setting.

Brandon Scalea

Latest:

BTK Inhibitors Show Continued Promise in CLL

Brian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.

Brandon Tom, PharmD

Latest:

In-Office Dispensing Is Better Value

With increased competition, the challenge in-office dispensing practices now face is to prove the value of what they do.

Brandon Weckbaugh, MD

Latest:

Dr. Weckbaugh on the LIBRETTO-001 Trial in NSCLC

Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).

Brant Inman, MD

Latest:

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Breanne E. Terakedis, MD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Breast Cancer Broadcast/News

Breelyn A. Wilky, MD

Latest:

Dr Wilky on the Study of Zalifrelimab, Balstilimab, and Doxorubicin in Soft Tissue Sarcoma

Breelyn A. Wilky, MD, discusses the rationale for investigating the combination of zalifrelimab, balstilimab, and doxorubicin in patients with advanced/metastatic soft tissue sarcoma, and early results from a phase 2 trial.

Breelyn Wilky, MD

Latest:

Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.

Bren Simon Cancer Center

Brendan Curley, DO, MPH

Latest:

Canine Caring: A Therapy Dog for Cancer Patients

Princess Danger was never intended to be a therapy dog. She came into our home as a pet, a goofball who immediately stole our hearts. The funny thing is that she not only stole our hearts, but that of anyone who met her.